FGF23 and X-linked hypophosphatemia: Though the availability of novel therapeutic strategies for XLH, namely anti-FGF23 antibodies, has recently changed XLH landscape, the results of this study may help prescribing a more individualized treatment as the disease manifestations are very variable between patients even in affected siblings.